Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Dr. Fernando Arocena Lanz].

Archivos espanoles de urologia·2015
Same author

[Impact of predictive models and decision making in prostate cancer: An integral debate].

Archivos espanoles de urologia·2011
Same author

Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009.

Archivos espanoles de urologia·2010
Same author

[Prostatic-rectal fistula after trasurethral resection of the prostate].

Archivos espanoles de urologia·2010
Same author

[Inguinal ureteral hernia: a clinical case].

Archivos espanoles de urologia·2009
Same author

An infrequent complication of a penile prosthesis.

Archivos espanoles de urologia·2009

Related Experiment Video

Updated: Jun 20, 2026

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

[Pulmonary fibrosis and endovesical mitomycin C].

José M Janeiro Pais1, Vicente Pastor Casas Agudo, Daniel López Garcia

  • 1Servicio de Urología, Hospital Juan Canalejo, La Coruña, España. janeiropais@canalejo.org

Actas Urologicas Espanolas
|September 18, 2009
PubMed
Summary

Mitomycin C, used for bladder cancer, can cause rare but fatal lung disease. This case highlights a severe respiratory adverse effect from endovesical instillation, even when considered safe.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Mitomycin C is a chemotherapeutic agent utilized for various carcinomas.
  • It has been administered via endovesical instillations for superficial bladder carcinoma for over 25 years.
  • Systemic administration is associated with known adverse effects like myelosuppression and pulmonary fibrosis.

Observation:

  • A patient developed a respiratory illness consistent with interstitial lung disease.
  • This condition progressed to severe respiratory insufficiency.
  • The patient ultimately died following endovesical Mitomycin C administration.

Findings:

  • The presented case details a fatal respiratory illness following endovesical Mitomycin C instillation.
  • This adverse effect, interstitial lung disease leading to death, is exceptionally rare for this route of administration.
  • The findings suggest a potential for severe pulmonary toxicity even with localized drug delivery.

Implications:

  • This case underscores the importance of vigilance for rare but severe adverse effects of Mitomycin C.
  • It prompts further investigation into the mechanisms of pulmonary toxicity from endovesical chemotherapy.
  • Clinicians should consider the potential for severe respiratory complications in patients receiving endovesical Mitomycin C.